Colorectal Cancer
Conditions
Keywords
stage IV colon cancer, stage IV rectal cancer, recurrent colon cancer, recurrent rectal cancer
Brief summary
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving cetuximab together with combination chemotherapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving cetuximab together with combination chemotherapy works as first-line therapy in treating patients with metastatic colorectal cancer.
Detailed description
OBJECTIVES: Primary * Determine the complete response rate in patients with metastatic colorectal cancer treated with cetuximab and FOLFIRINOX chemotherapy comprising oxaliplatin, irinotecan hydrochloride, leucovorin calcium, and fluorouracil as first-line therapy. Secondary * Determine the objective response rate in patients treated with this regimen. * Assess the tolerability of this regimen in these patients. * Determine the time to response and time to progression in patients treated with this regimen. * Determine the survival of patients treated with this regimen. OUTLINE: This is a multicenter study. Patients receive cetuximab IV over 1-2 hours on days 1 and 8. Patients also receive FOLFIRINOX chemotherapy comprising oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 30-90 minutes, and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours on days 1 and 2. Treatment repeats every 15 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed every 3 months.
Interventions
BIOLOGICALcetuximab
DRUGfluorouracil
DRUGirinotecan hydrochloride
DRUGleucovorin calcium
DRUGoxaliplatin
Sponsors
Institut du Cancer de Montpellier - Val d'Aurelle
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically confirmed colorectal cancer * Metastatic, unresectable disease * May or may not express the EGFR gene * Measurable disease, defined as ≥ 1 measurable lesion by MRI or CT scan * Lesion must be outside an irradiated area PATIENT CHARACTERISTICS: * WHO performance status 0-1 * Life expectancy \> 3 months * ANC ≥ 1,500/mm³ * Platelet count ≥ 100,000/mm³ * Hemoglobin ≥ 9 g/dL * Total bilirubin ≤ 1.5 times upper limit of normal (ULN) * Transaminases ≤ 2.5 times ULN (5 times ULN if hepatic metastases are present) * Creatinine ≤ 1.5 times ULN * Not pregnant or nursing * Fertile patients must use effective contraception * No peripheral or symptomatic neuropathy ≥ grade 2 (NCI-CTCAE) * No complete or partial intestinal blockage * No intestinal inflammatory disease (e.g., Crohn's disease or ulcerative colitis) * No chronic diarrhea * No severe unstable cardiac disease (despite treatment) * No myocardial infarction within the past 6 months * No neurological or psychiatric illness, including epilepsy or dementia * No uncontrolled active infection * No other prior or concurrent malignancy within the past 5 years except for curatively treated basal cell skin cancer * No psychological, familial, social, or geographic reason that would preclude study follow-up PRIOR CONCURRENT THERAPY: * No prior chemotherapy for metastatic disease * Prior fluorouracil-based adjuvant chemotherapy allowed provided it was administered ≥ 4 weeks ago * At least 4 weeks since prior and no other concurrent experimental therapy * No prior irinotecan hydrochloride, oxaliplatin, or monoclonal antibody * No prior intestinal resection (e.g., hemicolectomy or extended resection of the small intestine)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete response rate | 6 months |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate | 6 months |
| Adverse events by using NCI-CTC | 6 months |
| Time to response | 6 months |
| Time to progression | 6 months |
| Survival | 6 months |
Countries
France
Contacts
STUDY_CHAIRMarc Ychou, MD, PhD
Institut du Cancer de Montpellier - Val d'Aurelle
Outcome results
None listed